Home > Oncology > New data sets stage for broader use of AstraZeneca breast cancer drug

New data sets stage for broader use of AstraZeneca breast cancer drug

Conference
ASCO 2022
Reuters - 06/06/2022 - AstraZeneca and Daiichi Sankyo's Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy, according to data presented on Sunday. The data, unveiled at the American Society of Clinical Oncology (ASCO) meeting in Chicago, could open a large, new multibillion-dollar patient population for the drug that won U.S. approval in late 2019 as a third-line treatment for the 15% of breast cancer patients with HER2-positive disease. The ongoing phase III trial involves over 550 patients with so-called HER2-low breast cancer - most with tumours that were hormone-sensitive - whose disease had spread and had undergone at least one round of chemotherapy. The interim analysis showed Enhertu prolonged survival by an additional 6.4 months in patients with hormone-sensitive tumours. Patients in the group lived for a median of 23.9 months versus 17.5 months for chemotherapy.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on